XM无法为美国居民提供服务。
R
R

Regeneron

市场新闻

Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug

BUZZ-Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug ** Shares of drugmaker Amgen AMGN.O fall 1% to $324.95 ** Truist Securities downgrades stock to "hold" from "buy", citing "extremely competitive" landscape for an experimental drug to treat atopic dermatitis or eczema ** Brokerage also raises PT to $33
A
R
S

Teva to pay $450 million to resolve US kickback, price-fixing cases

UPDATE 1-Teva to pay $450 million to resolve US kickback, price-fixing cases Adds details on settlement, background of case throughout By Nate Raymond BOSTON, Oct 10 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA has agreed to pay $450 million to resolve allegations it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone and conspired to fix prices for generic drugs.
R
T

Clearside jumps as eye disease drug succeeds in mid-stage trial

BUZZ-Clearside jumps as eye disease drug succeeds in mid-stage trial ** Shares of drug developer Clearside Biomedical CLSD.O rise ~38.5% to $2.05 premarket ** Company says its drug CLS-AX showed stable vision in patients with wet age-related macular degeneration for up to 6 months compared to Regeneron Pharmaceuticals' REGN.O aflibercept, during a
R

Regeneron Pharmaceuticals Says Acquired IPR&D Charge Expected To Negatively Impact Q3 Adjusted EPS By About $0.43

BRIEF-Regeneron Pharmaceuticals Says Acquired IPR&D Charge Expected To Negatively Impact Q3 Adjusted EPS By About $0.43 Oct 7 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PHARMACEUTICALS - EXPECTS Q3 RESULTS WILL INCLUDE ACQUIRED IPR&D CHARGE OF ABOUT $56 MILLION ON PRE-TAX BASIS REGENERON PHARMACEUTICALS INC - ACQUIRED IPR&D CHARGE
R

Regeneron loses key defense in 19 treatment patent lawsuit

Regeneron loses key defense in COVID-19 treatment patent lawsuit By Blake Brittain Oct 4 - Biotech company Regeneron Pharmaceuticals REGN.O lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment. U.S. District Judge Philip Halpern rejected Regeneron's pretrial argument that he should throw out Allele Biotechnology and Pharmaceuticals' patent lawsuit over the treatment based on a federal law allowing the use of patented invent
P
R

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明